Literature DB >> 1859203

Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells.

H Ochiai1, M Kurokawa, S Niwayama.   

Abstract

We investigated the influence of the anticalmodulin drug, trifluoperazine (TFP) on influenza virus growth in MDCK cells. The inhibitory effect of TFP on virus growth was observed even when TFP was added at a late stage of infection. This inhibitory effect was concentration-dependent in the concentration range of 20-35 microM. At 35 microM, TFP caused a complete alteration in the distribution pattern of hemagglutinin (HA), concomitant with a decrease in the appearance of HA on the cell surface. After removal of the drug, the HA gradually began to show a normal distribution pattern and reappeared on the cell surface. The time course of rearrangement of HA was in accord with that of the recovery of cell supernatant infectivity. Scanning electron microscopic study revealed that the drug did not cause accumulation of the progeny viruses on the cell surface. The drug effect on the virus growth was reversed by the simultaneous presence of purified calmodulin (CaM). These data suggest that TFP acts as a reversible inhibitor of influenza virus morphogenesis, but not budding, by disturbing cellular CaM and/or CaM-dependent functions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859203     DOI: 10.1016/0166-3542(91)90032-m

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  6 in total

1.  Inhibition of MLC phosphorylation restricts replication of influenza virus--a mechanism of action for anti-influenza agents.

Authors:  Mehran Haidari; Wei Zhang; Leila Ganjehei; Muzammil Ali; Zhenping Chen
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

Review 2.  Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

Authors:  Thomas Pietschmann
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

3.  Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity.

Authors:  Theresa Enkirch; Svenja Sauber; Danielle E Anderson; Esther S Gan; Dimitar Kenanov; Sebastian Maurer-Stroh; Veronika von Messling
Journal:  Front Immunol       Date:  2019-06-05       Impact factor: 7.561

4.  Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo.

Authors:  Haoran Peng; Cuiling Ding; Liangliang Jiang; Wanda Tang; Yan Liu; Lanjuan Zhao; Zhigang Yi; Hao Ren; Chong Li; Yanhua He; Xu Zheng; Hailin Tang; Zhihui Chen; Zhongtian Qi; Ping Zhao
Journal:  Sci China Life Sci       Date:  2021-12-24       Impact factor: 10.372

5.  Screening differential miRNAs responsible for permeability increase in HUVECs infected with influenza A virus.

Authors:  Shujing Zhang; Ying Wu; Zinan Xuan; Xiaoming Chen; Junjie Zhang; Dongyu Ge; Xudan Wang
Journal:  PLoS One       Date:  2017-10-23       Impact factor: 3.240

6.  A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.

Authors:  Fangyuan Chen; Qingya Shi; Fen Pei; Andreas Vogt; Rebecca A Porritt; Gustavo Garcia; Angela C Gomez; Mary Hongying Cheng; Mark E Schurdak; Bing Liu; Stephen Y Chan; Vaithilingaraja Arumugaswami; Andrew M Stern; D Lansing Taylor; Moshe Arditi; Ivet Bahar
Journal:  Mol Syst Biol       Date:  2021-08       Impact factor: 11.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.